Nothing Special   »   [go: up one dir, main page]

Jump to content

O-2372

From Wikipedia, the free encyclopedia
O-2372
Identifiers
  • 6-((6aR,10aR)-1-hydroxy-6,6,9-trimethyl-6a,7,10,10a-tetrahydro-6H-benzo[c]chromen-3-yl)-6-methyl-1-morpholinoheptan-1-one
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC28H41NO4
Molar mass455.639 g·mol−1
3D model (JSmol)
  • CC1(C)[C@H]2[C@@H](CC(C)=CC2)C3=C(C=C(C(C)(C)CCCCC(N4CCOCC4)=O)C=C3O)O1
  • InChI=1S/C28H41NO4/c1-19-9-10-22-21(16-19)26-23(30)17-20(18-24(26)33-28(22,4)5)27(2,3)11-7-6-8-25(31)29-12-14-32-15-13-29/h9,17-18,21-22,30H,6-8,10-16H2,1-5H3/t21-,22-/m1/s1 ☒N
  • Key:ASKNFEPPYVJXIA-FGZHOGPDSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

O-2372 is an analgesic cannabinoid derivative created by Organix Inc. for use in scientific research. It has high affinity for both CB1 and CB2 receptors, with Ki values of 1.3 nM at CB1 and 0.57 nM at CB2, but is only moderately soluble in water compared to other related compounds such as O-2694, which it is a metabolite of.[1]

See also

[edit]

References

[edit]
  1. ^ Martin BR, Wiley JL, Beletskaya I, Sim-Selley LJ, Smith FL, Dewey WL, Cottney J, Adams J, Baker J, Hill D, Saha B, Zerkowski J, Mahadevan A, Razdan RK (September 2006). "Pharmacological characterization of novel water-soluble cannabinoids". The Journal of Pharmacology and Experimental Therapeutics. 318 (3): 1230–9. doi:10.1124/jpet.106.104109. PMID 16757541. S2CID 14864925.